Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nimotuzumab Combined With Paclitaxel as Second-line Treatment for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma With EGFR Over-expression: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial

NCT05978050 is registered in ClinicalTrials.gov with Biotech Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05978050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05978050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nimotuzumab Combined With Paclitaxel as Second-line Treatment for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma With EGFR Over-expression: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial
Lead sponsor
Biotech Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
August 1, 2024
Completion date
March 1, 2026
Enrollment
354 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric or esophagogastric junction adenocarcinoma